EGFR and neoplasm: As an example, a patient’s tumor may have developed heterogenous resistance to osimertinib, with some cells acquiring an EGFR C797S mutation that prevents osimertinib binding, and some cells entering a more quiescent, or drug-tolerant persister state [18].